What are the common side effects of Singular (montelukast) in patients with asthma and allergies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Side Effects of Singulair (Montelukast)

Montelukast is generally well-tolerated with a side effect profile similar to placebo, with the most common adverse effects being headache, upper respiratory infection, abdominal pain, and importantly, neuropsychiatric symptoms including mood changes, depression, and suicidal thoughts that warrant FDA black-box warning. 1

Most Common Side Effects in Adults and Adolescents (≥15 years)

The following adverse effects occurred in ≥1% of patients and more frequently than placebo in clinical trials 1:

  • Headache (18.4% vs 18.1% placebo) - the most frequently reported side effect 1
  • Upper respiratory infection (1.9% vs 1.5% placebo) 1
  • Asthenia/fatigue (1.8% vs 1.2% placebo) 1
  • Abdominal pain (2.9% vs 2.5% placebo) 1
  • Cough (2.7% vs 2.4% placebo) 1
  • Influenza (4.2% vs 3.9% placebo) 1
  • Dyspepsia (2.1% vs 1.1% placebo) 1
  • Dizziness (1.9% vs 1.4% placebo) 1
  • Nasal congestion (1.6% vs 1.3% placebo) 1
  • Rash (1.6% vs 1.2% placebo) 1

Common Side Effects in Pediatric Patients (6-14 years)

The following occurred with ≥2% frequency and more than placebo 1:

  • Pharyngitis, influenza, fever, sinusitis 1
  • Nausea, diarrhea, dyspepsia 1
  • Otitis, viral infection, laryngitis 1

Common Side Effects in Young Children (2-5 years)

The following occurred with ≥2% frequency and more than placebo 1:

  • Fever, cough, abdominal pain, diarrhea 1
  • Headache, rhinorrhea, sinusitis, otitis 1
  • Influenza, rash, ear pain, gastroenteritis 1
  • Eczema, urticaria, varicella, pneumonia 1

Serious Neuropsychiatric Side Effects (FDA Black-Box Warning)

The FDA has issued a black-box warning regarding neuropsychiatric events that can occur with montelukast 1:

  • Agitation including aggressive behavior or hostility 1
  • Depression and suicidal thoughts/actions (including completed suicide) 1
  • Anxiety, bad/vivid dreams, hallucinations 1
  • Irritability, restlessness, sleep walking 1
  • Tremor, trouble sleeping 1

Patients must be counseled about these risks and monitored for unusual behavioral or mood changes when starting montelukast 1.

Less Common but Important Side Effects

The following have been reported in post-marketing surveillance 1:

  • Allergic reactions including facial/lip/tongue/throat swelling that may cause breathing difficulty, hives, and itching 1
  • Increased bleeding tendency 1
  • Drowsiness, pins and needles/numbness, seizures 1
  • Palpitations, nose bleeds 1
  • Hepatitis 1
  • Joint pain, muscle aches and cramps 1
  • Inflammation of the pancreas 1

Laboratory Abnormalities

Mild elevations in liver enzymes occurred in approximately 2% of patients 1:

  • ALT increased (2.1% vs 2.0% placebo) 1
  • AST increased (1.6% vs 1.2% placebo) 1

Safety Profile Across Studies

Large real-world studies confirm the favorable safety profile 2, 3:

  • In a study of 694 patients, adverse effects occurred in only 18% and included abdominal discomfort, fever, fatigue, headache, rash, and upper respiratory symptoms 2
  • In a phase IV study of 5,855 adults, adverse drug reactions occurred in only 14 patients (0.23%), with no serious adverse events 3
  • The side effect profile remains consistent with prolonged treatment and does not significantly change over time 1

Critical Clinical Caveat

Montelukast's side effects are generally mild and comparable to placebo in frequency, making it one of the better-tolerated asthma and allergic rhinitis medications 1, 4, 5. However, the neuropsychiatric effects, though uncommon, are serious enough to warrant the FDA black-box warning and require patient education and monitoring 1.

Related Questions

What is the dose of Montelukast (Singulair) inhaler and how should it be administered?
What is the dosing regimen for montelukast (Singulair) in a 50kg adult patient with community-acquired pneumonia, Pseudomonas infection risk, and a history of asthma or allergic rhinitis?
What is Montelukast (Singulair) used for?
What is the risk-benefit profile of montelukast (Singulair) in terms of safety?
Can an asthma patient take montelukast (Singulair) plus levocetirizine (Xyzal) for 30 days?
Can you give me an example of a published study that utilized the STAR (Symptom Tracking and Reporting) platform in patients with advanced solid tumors, such as breast, lung, and colorectal cancer, receiving outpatient chemotherapy?
What is the diagnosis and management for a patient with gradual painless progressive loss of vision in both eyes, limited to counting fingers at 2.5 meters, with a grayish-white lens appearance and iris shadow?
How to manage a patient experiencing a singular side effect from a medication?
What is the best approach for managing symptoms and improving quality of life in patients with advanced solid tumors, such as breast, lung, and colorectal cancer, who are receiving outpatient chemotherapy and do not require a new medication or intervention?
What is the best approach for tumor lysis syndrome prophylaxis and monitoring of liver and renal function in a patient with a high white blood cell count, potential diagnosis of polycythemia vera, and mildly coarsened liver echotexture?
What are some examples of effective symptom management strategies for patients with advanced solid tumors receiving outpatient chemotherapy, including non-pharmacological interventions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.